SCHEMBL5378069

SCHEMBL5378069

CSc1nsc(OCc2ccc(C)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AGXT P21549 2/20 0.37
MAPT P10636 1/20 0.36
MAOB P27338 3/20 0.36
ALDH1A1 P00352 3/20 0.36
PIN1 Q13526 1/20 0.35
MPO P05164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5417437 0.88 MEN1 (0.41) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5378771 0.87 TDP1 (0.56) CYP1A2CYP2C9CYP2C19NPSR1KMT2A
SCHEMBL5381872 0.87 L3MBTL1 (0.56) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5378052 0.87 MEN1 (0.41) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5383575 0.87 APP (0.42) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5377736 0.86 LMNA (0.47) CYP1A2CYP2C9CYP2C19CYP3A4KMT2A
SCHEMBL5375690 0.85 RAB9A (0.45) CYP1A2CYP2C9CYP2C19KMT2AMEN1
SCHEMBL5398160 0.85 MEN1 (0.39) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5387366 0.84 APP (0.42) CYP1A2CYP2C9CYP2C19CYP3A4NPSR1
SCHEMBL5373469 0.83 MAOB (0.41) CYP1A2CYP2C9CYP2C19CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH CYP1A2 24/4885CYP2C9 107/4885CYP2C19 109/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH CYP1A2 30/4885CYP2C9 113/4885CYP2C19 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.